Subscribe

News
Video
Podcasts
Journals
Conferences
Events
Resources
CE
About AJMC
Subscribe

Spotlight -

Free In-Person Regional Events Focused on Oncology and Population Health

Opinion|Videos|August 5, 2024

Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

Key opinion leaders explore molecular characteristics beyond mutations that influence immunotherapy response in non small cell lung cancer treatment.

Episodes in this series

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 1 Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 2 Strategies to Increase Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 3 Limitations on Optimal Biomarker Testing Rates

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 4 Impact of Biomarker Testing on Treatment Selection and Outcomes

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 5 Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 6 NCCN Recommendations by PD-L1 Expression Level

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 7 Limitations of NCCN PD-L1 Expression Recommendations

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 8 Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 9 Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP. 10 Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

A panel of 4 experts on lung cancer

EP. 11 Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

A panel of 4 experts on lung cancer

EP. 12 Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

A panel of 4 experts on lung cancer

EP. 13 Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

Beyond genomic mutations like STK11/KEAP1/KRAS, are there other molecular characteristics that can influence immunotherapy effectiveness and should guide treatment selection?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Content

Investing in the Future: Redesigning Healthcare Infrastructure for CRM Excellence

ByIan J. Neeland, MD

June 16th 2026

Experts featured in this series.

Beyond the Prescription: Navigating Side Effects, Patient Agency, and Generic Variability

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 16th 2026 | Updated: June 16th 2026

Experts featured in this series.

From Uncertainty to Action: How Psychiatrists Navigate Complex Treatment Decisions

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 16th 2026 | Updated: June 16th 2026

From Reactive to Proactive: Evolving Health Systems for CRM Management

ByIan J. Neeland, MD

June 16th 2026

Experts featured in this series.

Provider Shortages and Diagnostic Complexity: The Compounding Challenges of Mental Health Care

ByPatrick Runnels, MD, MBA,Ginger Shupe, MD,Gus Alva, MD, DFAPA,Joe Goldberg, MD

Published: June 15th 2026 | Updated: June 15th 2026

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

EHA 2026 Had Something for Everyone, From Pediatric Practitioners to “Myeloma Maniacs”

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

How MCOs Should Be Preparing for the OBBBA's Medicaid Cuts: David Brueggeman, MBA

Monoclonal Antibodies Had Varying Efficacy in Treating MG